🔗 Share this article

Given that the US undertakes unprecedented changes to its immunization recommendations, one figure has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccines in the pandemic and has zeroed in on alleged deaths following COVID-19 vaccination in her recent time at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Immunization Schedule

Public health authorities had intended to announce sweeping revisions to the pediatric immunization program earlier this month, synchronizing the US with Denmark’s immunization schedule, it is understood – a significant shift that would put the US out of alignment with many the international standard with insufficient data for public health gain. The planned update has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is set to present at the gathering. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it signals a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has frequently advocated for halting specific childhood immunization guidelines in the US so as to align more similar to Denmark's approach, a society with universal health coverage and a number of inhabitants roughly the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Background

The appointee has no obvious track record in drug development, oversight or management, which has been standard for former directors of the CBER. She has served at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She is not versed in managing a large organization. She is not an expert in pharmaceutical oversight.”

Previous directors of the center would “understand laws and regulations and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she lacks the type of experience that former directors who headed the center have had.”

This division has an vast workload at the agency, Woodcock pointed out.

“Many people just pays attention on the new drug program, but the generic drug division approves a multitude of generic medications. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these have to be looked after,” she said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial leadership element to the position, which supervises more than 5,000 personnel. “It’s a massive leadership role, if you perform it correctly,” she concluded.

Agency Reaction and Contentious Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this selection represents increased cooperation among agency officials on immunizations, a representative stated that the “questions are based on incorrect assumptions”.

“This background matches the duties of her position,” the spokesperson stated, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a disputed expedited medication authorization process that reportedly troubled her preceding directors. “How are these medications being chosen for this expedited pathway? Who is making the calls?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the agency right now.”

Overall, he stated, “the agency looks to be trending towards less stringent regulations of all drugs, aside from shots.”

Established Track Record on Vaccines

Concerning immunizations, Høeg has a more documented, if problematic, history, some experts observe. She published a research paper using unverified crowd-sourced reports to estimate the rate of heart inflammation following Covid immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the current federal leadership encompassed revising regulations for recently developed shots and discontinuing “optional” vaccines, she remarked after the election on a audio program. At the FDA, Dr. Høeg has allegedly floated the idea of excluding adolescent males from getting COVID-19 vaccinations.

“She is an all-around true believer who begins with her conclusions and reverse-engineers to retrofit the evidence in a very deceptive, untruthful manner,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg became part of other contrarians, {like|